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ABstRACt
Objective: To outline the epidemiological profile and prognosis 
for Ewing’s sarcoma in the Brazilian population. Material and 
Methods: The medical records of 64 patients with intraosseous 
Ewing’s sarcoma who were treated at the Pediatric Oncology 
Institute, IOP-GRAACC-Unifesp, between 1995 and 2010, were 
retrospectively evaluated. Results: The statistical analysis on 
the data obtained did not correlate factors such as sex, trauma, 
INtRODUCtION
Ewing’s tumor was described by James Ewing in 1921, 
and is a high-grade osteolytic malignant neoplasm(1). It 
is the third commonest primary malignant bone tumor, 
after multiple myeloma and osteosarcoma. Among 
children and young adults, it is the second in frequency 
after osteosarcoma, and in the population under the age 
of 15 years, it is the most frequent type(2-5). Cases are 
mainly diagnosed in the second decade of life, while 20-
30% are in the first decade and occurrences are rare in 
individuals over the age of 30 years and under the age of 
five years(6). It is extremely rare in Afrodescendent and 
Asian populations and is slightly more frequent among 
males(4). The estimated five-year survival in cases of 
localized disease, i.e. non-metastatic cases, is between 
50 and 70%, according to the worldwide literature(7-9). 
The emergence of chemotherapy in the 1970s and its 
evolution have contributed towards improvements in 
prognoses; however, in cases of metastatic disease, the 
prognosis remains unfavorable and survival continues 
to be between 18 and 30%(1,8,10-12). The lungs are the 
commonest site for metastases (50%) and, in isolated 
occurrences, the results presented are slightly better 
than in cases of extrapulmonary metastasis. Symptoms 
such as pain and edema have been attributed mainly 
to the growth of bone lesions, and these tend to be the 
first sign of the disease. The time that elapses until the 
diagnosis is made ranges from three to nine months, 
according to the literature, thus delaying the start of 
oncological treatment(13,14).
Ewing’s tumor most frequently affects the pelvis, 
femur, tibia, humerus and thoracic wall, but it may affect 
any bone. It is commonest in the long bones, such as the 
femur and tibia, and is typically a diaphyseal lesion(12,15).
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pathological fracture and time taken for case diagnosis with 
the treatment outcome. Factors such as initial metastasis, lung 
metastasis, tumor site, age, recurrence and type of surgery 
showed results corroborating what has been established in 
the literature. Conclusion: The prognosis in cases of Ewing’s 
sarcoma was mainly influenced by the presence of metastases at 
the time of diagnosis.
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MEtHOD
This was a retrospective study based on reviewing 
the database of all the patients registered in the On-
cological Orthopedics Sector of the Federal Univer-
sity of São Paulo, and in this university’s Institute 
of Pediatric Oncology (IOP-GRAACC-Unifesp). 
Between January 1, 1995, and December 31, 2010, 
64 patients with Ewing’s tumor underwent oncolo-
gical treatment at our clinic. All the medical files 
were reviewed to seek data on sex, age, staging, 
clinical signs and symptoms, surgical procedures, 
location of the lesions, anatomopathological results, 
local recurrence and oncological clinical outcome. 
All the patients received neoadjuvant and adjuvant 
chemotherapy. All the patients underwent local le-
sion control, which was by means of surgery, radio-
therapy, or both.
For the statistical analysis, the relationships be-
tween age, sex, site, presence of pathological frac-
tures, radiotherapy with late metastatic outcomes, 
late pulmonary metastasis, recurrence and death were 
evaluated. The chi-square, Fisher and likelihood ratio 
tests were used. To analyze estimates of mean length 
of survival, the Kaplan-Meier function and the results 
from log-rank test comparisons were used. All the 
data were analyzed using the SPSS software, version 
17.0 (SPSS, Inc., Chicago, IL, USA), and P-values 
< 0.05 were considered to be statistically significant.
REsULts
We found 26 female patients (40.6%) and 38 male 
patients (59.4%). Their mean age was 14.7 years 
(ranging from four to 30 years).
Among the 64 patients who underwent onco-
logical treatment, eight (12.5%) progressed to de-
ath and no orthopedic treatment was performed; 
three (4.6%) underwent amputation; nine (14.0%) 
only underwent radiotherapy; and 44 (68.7%) un-
derwent resection of the lesion. Among the lat-
ter, 18 cases (40.9%) were managed with surgery 
alone and 26 (59.1%) with surgery followed by 
radiotherapy. Over the course of the treatment, se-
ven patients (38.8%) who had been treated with 
surgery alone, 11 (42.3%) with surgery and radio-
therapy and four (44.4%) with radiotherapy alo-
ne evolved with metastasis. None of the patients 
who underwent amputation presented metastasis 
during the follow-up. There was local recurren-
ce in two patients (11.1%) who had been treated 
with surgery alone and in seven (26.9%) who had 
undergone surgery and radiotherapy. Among the 
patients who underwent limb-preserving surgery 
and reconstruction, an endoprosthesis was used 
in 10 (22.7%), followed by biological techniques
(Figure 1 A-C) in nine (20.4%) and tumor resection 
without reconstruction or other surgical techniques 
in 25 (56.8%). Among the patients who presented 
local recurrence, six (50%) evolved with late me-
tastasis; of these, three patients (50%) presented 
pulmonary and non-pulmonary metastasis and three 
(50%) presented non-pulmonary metastasis. In re-
lation to age, seven (23.3%) of the patients aged
≤ 12 years presented metastases at the time of diag-
nosis, and 12 (40%) presented late metastasis over 
the course of the treatment. Among the patients 
over the age of 12 years, 12 (35.2%) presented 
metastases at the time of diagnosis, and 11 (35.2%) 
presented late metastasis during the follow-up. The 
tumor affected the appendicular skeleton in 39 pa-
tients (61.0%) and the axial skeleton in 25 (39.0%). 
Of these cases, respectively 18 (46.1%) and five 
(20.0%) evolved with metastases. At the end of 
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Figure 1 – Ten-year-old patient with pain in the proximal region of the left humerus for 
three months: (A) radiograph showing mixed lesion (osteolytic and osteoblastic), with 
periosteal reactions in “sunray” pattern and presence of Codman triangle; (B) magne-
tic resonance imaging showing lesion in the proximal third of the humerus, invading 
the epiphysis, and also an extraosseous mass; (C) radiograph after resection of the 
lesion and reconstruction using vascularized fibular tissue, while preserving the fibular 
proximal epiphysis to enable growth.
B C
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the period analyzed, 31 patients (48.4%) did not 
present any evidence of disease, 11 (17.1%) were 
alive with metastases in the lungs or other locations 
and 22 (34.3%) had died due to their disease.
The mean length of time that elapsed until the 
patients in this study were diagnosed was approxi-
mately six months. Thirty-four patients were diag-
nosed with Ewing’s tumor within six months and 
among these, 15 (44.1%) presented late metastasis 
and 14 (41.1%) died. For 30 patients, the diagnosis 
was made after more than six months and among 
these, six (20%) presented late metastasis and six 
(20%) progressed to death.
DIsCUssION
Ewing’s tumor is the third commonest malig-
nancy of bone origin, in order of incidence, only 
behind multiple myeloma and osteossarcoma. In 
the population under the age of 15 years, it is the 
leader in incidence. Our patients’ ages were con-
centrated between four and 30 years. Age is a prog-
nostic factor in the literature(16,17), and this was ob-
served in our sample, with lower five-year survival 
among patients over the age of 12 years (50.2%), 
compared with patients under the age of 12 years 
(71.7%) (P = 0.075). The mean age of the patients 
with pulmonary metastasis was slightly lower than 
the mean age among patients with extrapulmonary 
metastasis (respectively, P = 0.501 and P = 0.261), 
thus contrasting with local recurrence, which occur-
red in slightly older patients (P = 0.592).
We did not observe any differences in sex, trau-
ma or pathological fractures, in relation to pulmo-
nary metastases, extrapulmonary metastases, local 
recurrence and total number of deaths (Table 1). We 
did not study the size of the lesion or the degree of 
tumor necrosis, since the data were not available in 
the files. These parameters are difficult to measure 
in cases of Ewing’s tumor because soft tissues are 
frequently a component and because of differences 
between the imaging examinations.
The general estimated five-year survival was 
59.5% (Figure 2), and in correlations with sex, loca-
tion and type of non-chemotherapeutic treatment, no 
statistical differences were presented (respectively, 
P = 0.361; P = 0.464 and P = 0.238).
The most frequent location in the appendicular 
table 1 – Comparative analysis on epidemiological factors and outcomes.
 Extrapulmonary metastasis*
Pulmonary 
metastasis* Recurrence* Death*
Sex 0.728 >0.999 0.53 0.615
Trauma 0.529 >0.999 0.42 0.745
Fracture 0.619 0.546 >0.999 0.118
* P values.
Figure 2 – Survival of the patients treated due to Ewing’s tumor.
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skeleton was in the femur (46%), followed by the 
tibia (35%) and humerus (8%). In relation to the 
axial skeleton, the innominate bone was affected 
in 44% of the cases, followed by the sacrum and 
spine in 20%. In the literature, an axial location for 
Ewing’s tumor (in the pelvis or spine) is a classical 
criterion for a poor prognosis(16). In our sample, late 
metastasis occurred more frequently in appendicu-
lar locations (45%; P = 0.051), in relation to axial 
locations (20.8%), which contradicts the hypothe-
sis of worse prognosis for lesions occurring in the 
axial skeleton, although this was probably due to the 
small number of patients. However, death occurred 
more commonly in cases with axial tumor locations 
(37.5%; P = 0.683), in comparison with appendicular 
locations (32.5%).
In cases of localized disease, the current treat-
ment may achieve a five-year disease-free survival 
rate of 50-70%. However, among patients with ini-
tial metastasis, this number only reaches 30%(8,12). 
The lungs are the commonest site for metastases 
(50%), and pulmonary metastases present better 
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prognosis than observed for extrapulmonary me-
tastases(2,11,14). In our sample, 57.1% of the patients 
with initial metastases died, whereas only 23.3% 
died among the patients who did not present initial 
metastasis (P = 0.007).
Ewing’s tumor, like other small and round-cell 
tumors, responds well to radiotherapy, and local 
control can be achieved through this therapeutic 
method alone(18). However, complications relating 
to radiotherapy in pediatric patients, such as lesions 
in growth cartilage or the risk of developing other 
secondary forms of neoplasia, restrict this method to 
inoperable tumors, which are mostly located in the 
pelvis and spine. Another indication related to local 
adjuvant treatment, when the surgical margins are 
seen to be compromised following tumor resection.
Among the patients in our sample who received 
radiotherapy, 41.7% evolved with late metastasis 
41.7% (P = 0.195), 25.7% with local recurrence
(P = 0.094) and 38.9% with death (P = 0.446). The 
prognosis for these patients was worse than among 
patients who did not receive this type of therapy: 
respectively 25.9%, 7.4% and 29.6%. Comparisons 
between the groups should be analyzed carefully, 
since patients who receive indications for radiothe-
rapy tend to present larger tumors in locations that 
are less favorable for resection(18).
Despite aggressive treatment, it is reported in the 
literature that around 20 to 40% of the patients with 
localized disease and 80% of the patients with me-
tastases evolve to death due to disease recurrence 
or progression(19). Most of the cases of recurrence 
occur after the termination of the treatment, such 
that 80% occur more than two years after the initial 
diagnosis. The time that elapses until recurrence is 
a major prognostic factor, such that the survival rate 
from recurrences occurring more than two years af-
ter the initial diagnosis is 25%, but it is less than 
10% among cases of early recurrence(11,20). In our 
sample, the mean survival among the patients who 
presented recurrence was 46 months, in contrast with 
the 73 months of survival among the patients who 
did not present recurrence (P = 0.495).
Despite the established importance of early diag-
nosis, the time that elapsed until diagnosis in our 
sample did not influence any of the variables: late 
metastasis (P = 0.219), late pulmonary metastasis 
(P = 0.903), local recurrence (P = 0.521), death
(P = 0.660) or five-year survival (P = 0.796). This 
leads us to believe that correct treatment is a more 
important factor than the time that elapses before it 
starts. This also corroborates the classical recommen-
dation that oncological patients should be referred to 
treatment centers, instead of starting with procedures 
such as biopsies in non-specialist hospitals, in order 
to accelerate reaching a diagnosis. 
Classically, Ewing’s tumor presents genetic ab-
normalities that can be identified in 80% of the 
cases, represented by the reciprocal translocation 
between chromosomes 11 and 22, i.e. t(11;22) 
(q24;q12), which results in expression of the pro-
tein EWS/FLI-1(21). Presence of this translocation 
in the tumor is a diagnostic factor for Ewing, but 
it is not prognostic. Presence of the same translo-
cation in the patient’s peripheral blood, or in bone 
marrow aspirate away from the area of tumor, is a 
sign of disseminated disease and therefore of poor 
prognosis(22). In our clinic, genetic analysis on this 
translocation began in 2008, but it has not yet been 
possible to assess these data.
CONCLUsION
From this study, we concluded that factors like 
sex, trauma, pathological fractures and time elapsed 
until the diagnosis did not modify the patients’ outco-
mes. Age at the time of the diagnosis was important, 
but it was also not decisive with regard to the result 
from the treatment. The majority of the patients un-
derwent orthopedic surgical treatment with preserva-
tion of the affected limb. The results were worse for 
patients with tumors in axial locations. Presence of 
an initial metastasis was the main factor for worse 
evolution among the patients, and this was statisti-
cally significant. The results should be assessed ca-
refully, because the limited number of patients makes 
it difficult to trace out a more accurate panorama of 
Ewing’s tumor in our population.
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